Insmed (NASDAQ:INSM) Insider Sells $2,964,945.24 in Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider owned 51,871 shares of the company’s stock, valued at $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, February 3rd, Michael Alexander Smith sold 640 shares of Insmed stock. The shares were sold at an average price of $156.27, for a total transaction of $100,012.80.
• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $241,968.68.

Insmed Stock Performance

INSM opened at $162.43 on Friday. The firm’s fifty day moving average is $150.30 and its two-hundred day moving average is $166.67. The firm has a market cap of $35.06 billion, a PE ratio of -25.34 and a beta of 1.10. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period last year, the firm earned ($1.32) EPS. Insmed’s quarterly revenue was up 152.6% on a year-over-year basis. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wolfe Research set a $167.00 price target on Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Guggenheim decreased their price objective on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. HC Wainwright increased their target price on Insmed from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Bank of America lifted their price target on shares of Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Royal Bank Of Canada upped their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $212.67.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently added to or reduced their stakes in INSM. CoreCap Advisors LLC acquired a new position in shares of Insmed during the 4th quarter worth about $27,000. Reflection Asset Management acquired a new stake in shares of Insmed in the fourth quarter valued at about $30,000. GraniteShares Advisors LLC bought a new stake in Insmed during the fourth quarter worth about $30,000. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in Insmed during the fourth quarter valued at approximately $32,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.